

FORM 3

UNITED STATES SECURITIES AND EXCHANGE
COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person * <u>Tanna Naresh Haresh</u> (Last) (First) (Middle) <u>C/O PRECISION BIOSCIENCES, INC.</u> <u>302 E. PETTIGREW STREET,</u> <u>SUITE A-100</u> (Street) <u>DURHAM NC 27701</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>08/01/2026</u>	3. Issuer Name and Ticker or Trading Symbol <u>PRECISION BIOSCIENCES INC [DTL]</u> Foreign Trading Symbol	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner ☒ Officer (give title below) Other (specify below) <u>Chief Financial Officer</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) ☒ Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned			
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	25,575	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)							
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Restricted Stock Units	(1)	(1)	Common Stock	5,561	(2)	D	
Restricted Stock Units	(3)	(3)	Common Stock	11,105	(2)	D	
Restricted Stock Units	(4)	(4)	Common Stock	30,000	(2)	D	
Restricted Stock Units	(5)	(5)	Common Stock	179,340	(2)	D	

Explanation of Responses:

1. On April 18, 2024, the reporting person was granted 16,683 restricted stock units ("RSUs"), which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Company through the applicable vesting dates.
2. The Reporting Person was granted RSUs, which each represents a contingent right to receive one share of the Company's Common Stock.
3. On August 22, 2024, the reporting person was granted 33,317 RSUs, which vest in three substantially equal annual installments beginning on January 27, 2025, subject to the Reporting Person's continued service to the Company through the applicable vesting dates.
4. On June 2, 2025, the reporting person was granted 45,000 RSUs, which vest in three substantially equal annual installments beginning on February 17, 2026, subject to the Reporting Person's continued service to the Company through the applicable vesting dates.
5. On June 1, 2026, the reporting person was granted 179,340 RSUs, which vest in three substantially equal annual installments beginning on February 19, 2027, subject to the Reporting Person's continued service to the Company through the applicable vesting dates.

Remarks:

Exhibit 24 - Power of Attorney

/s/ Dario Scimeca,
Attorney-in-Fact for
Naresh Tanna
** Signature of Reporting Person
08/03/2026
Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB

Power of Attorney

I, the person whose signature appears below, hereby appoint Dario Scimeca, General Counsel of Precision BioSciences, Inc. (the “Company”), John Alexander Kelly, Chief Financial Officer of the Company, Mei Burris, Vice President of Finance of the Company, and Alan Sharpe, Director of Financial Reporting of the Company, and each of them individually, as my attorneys-in-fact with the power and authority:

- to take such actions as may be necessary or appropriate to enable me or others on my behalf to submit and file forms, schedules and other documents with the U.S. Securities and Exchange Commission (the “SEC”) utilizing the SEC’s Electronic Data Gathering and Retrieval (“EDGAR”) system, which actions may include (1) enrolling me in EDGAR Next and (2) preparing, executing and submitting to the SEC a Form ID, amendments thereto, and such other documents and information as may be necessary or appropriate to obtain codes and passwords enabling filings and submissions to be made by me or others on my behalf utilizing the EDGAR system;
- to execute and file with the SEC on my behalf, pursuant to Section 16(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules thereunder, (1) an Initial Statement of Beneficial Ownership of Securities on Form 3, (2) Statements of Changes in Beneficial Ownership on Form 4 and (3) Annual Statements of Changes in Beneficial Ownership on Form 5, and any amendments thereto, in each case (clauses (1)–(3)) with respect to my service as a director and/or officer of the Company and my holdings of and transactions in Company securities of which I may be deemed the beneficial owner;
- to do and perform on my behalf any and all other acts necessary or desirable to complete, execute and timely file such Forms 3, 4 and 5 and any amendments thereto with the SEC and, if necessary, any stock exchange or similar authority, including but not limited to the power to designate any person then serving as a director or officer of the Company to be an additional or substitute attorney-in-fact under this Power of Attorney with the same power and authority as if such person were named herein, and to take any other action in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of or legally required by me, it being understood that the documents executed by such attorney-in-fact on my behalf pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as the attorney-in-fact may approve in his or her discretion;
- to act as an account administrator for my EDGAR account, including to (1) appoint, remove and replace account administrators, account users, technical administrators and delegated entities; (2) maintain the security of my EDGAR account, including modification of access codes; (3) maintain, modify and certify the accuracy of information on my EDGAR account dashboard; (4) act as the EDGAR point of contact with respect to my EDGAR account; and (5) take any other actions contemplated by Rule 10 of Regulation S-T with respect to account administrators; and
- to cause the Company to accept a delegation of authority from any of my EDGAR account administrators and, pursuant to that delegation, authorize the Company’s EDGAR account administrators to appoint, remove or replace users for my EDGAR account.

The authority granted under this Power of Attorney shall continue in effect for each attorney-in-fact named above until I am no longer required to file reports with respect to my holdings of and transactions in Company

securities, unless earlier revoked in a writing signed by me and delivered to such attorney-in-fact. This Power of Attorney revokes any and all powers of attorney I have previously executed in connection with my obligations as an officer, director or beneficial owner of the Company to prepare and file Forms 3, 4 and 5, or other forms or reports, or any amendment or amendments thereto, with the SEC and any stock exchange or similar authority, pursuant to Section 16(a) of the Exchange Act.

I acknowledge that neither the attorneys-in-fact nor the Company is assuming any of my responsibilities to comply with Section 16 of the Exchange Act.

IN WITNESS WHEREOF, I have signed this Power of Attorney on the date shown below.

/s/ Naresh Tanna
Signature